This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q05.8 (sacral spina bifida without hydrocephalus) | Special Copayment Reduction: V179 (rare disease) |
| B. Synonyms | Sacral spina bifida without hydrocephalus |
| C. Adult onset | Likelihood of first onset in adulthood: very low — sacral spina bifida is a congenital spinal malformation, mostly diagnosed at birth or in the neonatal period. Occasionally, spina bifida occulta exists without skin abnormalities and is discovered incidentally in adulthood, but this is an asymptomatic finding rather than symptom onset. |
| 1. History | Sacral spina bifida is a caudal lesion of the spina bifida spectrum; it was first described in 19th-century anatomical pathology, and systematic treatment was established with the development of neurosurgery in the 20th century. |
| 2. Causes | Common risk factors for neural tube defects such as folate deficiency, maternal diabetes, antiepileptic drug (valproic acid) exposure, and MTHFR polymorphisms. Occurrence specific to the sacral level is associated with defects in caudal neural tube closure (secondary neurulation). |
| 3. Genetics | Multifactorial inheritance. Associated with VANGL1/2, MTHFR, CELSR1 variants. Familial recurrence risk about 3–5%. About 20–25% of spina bifida occurs at the sacral level. |
| 4. General epidemiology | The sacral level accounts for about 20–25% of all spina bifida. The most common level after lumbar. Incidence trending down after folic acid fortification policies. Registered disease under Korean Special Copayment Reduction V179. |
| 5. Pathophysiology | Defects at the sacral·coccygeal level result from defective secondary neurulation at 4–5 weeks of gestation. Absence of hydrocephalus means Chiari II malformation is mild or absent and cerebrospinal fluid circulation is maintained. |
| 6. Symptoms | Loss of sensation in the perineum·perianal area, bladder·rectal dysfunction (neurogenic bladder·bowel), distal lower limb weakness, foot deformity, sexual dysfunction. Lower limb function relatively preserved compared with upper lumbar levels. |
| 7. Signs | Dermal sinus·lipoma·dimple at the sacral·coccygeal region, loss of the anal reflex, residual urine in the bladder, decreased ankle·toe reflexes, loss of perineal sensation. Spinal MRI findings of tethered cord or lipomyelomeningocele. |
| 8. Screening | Maternal serum AFP, detailed ultrasound at 18–22 weeks of gestation (confirmation of sacral vertebral arch defect), supplementary fetal MRI, high-dose folic acid supplementation and intensified prenatal follow-up for high-risk groups. |
| 9. Diagnosis | Sacral defect confirmed by prenatal ultrasound·MRI. After birth: spinal MRI (tethered cord·lipomyelomeningocele), urodynamic studies, renal ultrasound, anorectal manometry, neurophysiological testing. |
| 10. Treatment | Surgical closure of the spinal cyst (open type), untethering of the tethered cord, clean intermittent self-catheterization, anticholinergics, bowel management program, orthoses, orthopedic correction of foot deformities, multidisciplinary rehabilitation. |
| 11. Prognosis | Sacral-level lesions have relatively preserved lower limb motor function (high proportion able to walk). Bladder·rectal dysfunction is the main chronic problem. Renal function can be preserved with early urologic management. Cognitive function normal. |
| 12. Prevention | Folic acid 400–800 μg/day before and in early pregnancy. 5 mg/day for high-risk groups. Management of risk factors (diabetes, antiepileptic drugs). Active prenatal screening (MSAFP, detailed ultrasound). |
| 13. References | Copp AJ et al. Lancet Neurol 2013; Mitchell LE et al. Lancet 2004 and 8 others |
Sacral spina bifida is a congenital defect occurring at the sacral level, the most caudal part of the spine within the spina bifida spectrum. The first systematic description of spina bifida was made in 1641 by Nicolaas Tulp of the Netherlands, and in the 19th century German and British anatomical pathologists described various anatomical variants of posterior vertebral arch defects. Sacral-level lesions tend to involve less neurological damage than lumbar lesions and often show a relatively mild clinical course.
With the development of neurosurgery in the mid-20th century, closure of myelomeningocele was standardized, and, independent of Judith Graham Pool's discovery of cryoprecipitate in 1964, the key advances in the field of spina bifida were surgical closure of meningoceles and myelomeningoceles and urodynamic management. The introduction of urodynamic techniques in the 1970s–80s enabled accurate classification and management of neurogenic bladder, and the paradigm of bladder management changed after clean intermittent catheterization (CIC) was introduced by Lapides et al. in 1972.
In the field of prenatal diagnosis, the introduction of maternal serum AFP testing and fetal ultrasound in the 1970s enabled prenatal detection of neural tube defects, including spina bifida. After the preventive effect of folic acid against spina bifida was demonstrated in the 1991 MRC randomized controlled trial, recommendations for folic acid supplementation were included in health policies worldwide. In Korea, since the 2000s, the incidence of spina bifida has been trending down owing to the Ministry of Health and Welfare (MOHW) policy of free folic acid distribution to pregnant women and improved quality of prenatal ultrasound screening. Recently, results of fetal in utero spinal closure (MOMS trial, 2011) have been reported, but whether fetal intervention is indicated when only a sacral-level lesion is present must be judged individually.
A notable point in the history of sacral spina bifida is the rediscovery of spina bifida occulta. It is not uncommon for a sacral vertebral arch defect to be discovered incidentally when lumbar MRI is performed in adults for low back pain or bladder dysfunction, and some show neurological symptoms associated with tethered cord syndrome. As a result, sacral spina bifida occulta has become a condition that can also be encountered in adult neurosurgery outpatient clinics.
Sacral spina bifida occurs when a defect arises in the process of caudal neural tube closure in the embryo at about 4–5 weeks of gestation. Neural tube formation at the lumbar level and above occurs by primary neurulation, whereas the sacral·coccygeal levels are completed by secondary neurulation — canalization of the caudal cell mass. Defects in this secondary neurulation process form the specific pathophysiological basis of sacral spina bifida.
The causal risk factors are mostly shared with lumbar spina bifida. Folate deficiency is the most important environmental factor, and folic acid supplementation before and in early pregnancy can prevent about 50–70% of all neural tube defects. The MTHFR C677T homozygous (TT) type reduces the efficiency of folate metabolism, increasing NTD risk. Maternal diabetes (poor glycemic control) particularly affects development of the caudal cell mass and may be associated with sacral·lumbosacral-level defects. Some animal studies have reported that hyperglycemia selectively interferes with secondary neurulation.
Antiepileptic drug exposure: valproic acid disrupts the gene expression needed for neural tube closure through histone deacetylase inhibition (HDAC inhibition). In fetuses exposed to valproic acid in early pregnancy, the risk of spina bifida rises to about 1–2%, with increased risk across all levels, including the sacral level. Carbamazepine is associated with a small increase in risk. Obesity (BMI ≥30) is also reported as an independent risk factor, with insulin resistance and impaired folate absorption proposed as mediating mechanisms.
Genetic factors: spina bifida, including sacral spina bifida, follows a multifactorial mode of inheritance. When a previous affected child has been born, the recurrence risk is about 3–5%. Variants in PCP pathway genes (VANGL1, VANGL2, SCRIB, CELSR1) and transcription factors (FOXC2, T/BRACHYURY) have been reported to be associated with sacral·lumbosacral-level defects. Caudal regression syndrome is a more extensive defect of caudal structures associated with maternal diabetes and needs to be differentiated from sacral spina bifida.
The genetic architecture of sacral spina bifida, like that of lumbar spina bifida, follows a multifactorial mode of inheritance. Cases due to a single-gene defect are few, and most arise from the interaction of multiple genetic variants and environmental factors. Familial clustering of spina bifida is observed, and the concordance rate in monozygotic twins is about 50–70%, suggesting that genetic factors play an important role in its occurrence.
MTHFR gene polymorphisms: MTHFR C677T TT homozygosity reduces enzyme activity by about 70%, impairing the production of 5-methyltetrahydrofolate (5-MTHF) and raising homocysteine. This genotype increases NTD risk by about 1.5–2 times, and the risk is offset when folic acid supplementation is sufficient. The A1298C polymorphism confers additional risk in compound heterozygosity with C677T. MTHFR testing can be used as reference information in preconception counseling when there is a family history of NTD.
Planar cell polarity (PCP) pathway: loss-of-function variants in the VANGL1, VANGL2, CELSR1, SCRIB, and PRICKLE genes have been reported in human NTD patients. These genes regulate cell orientation and convergent extension movements and are essential for neural tube closure. In mouse models, homozygous Vangl2 variants cause craniorachischisis, and heterozygous variants increase the occurrence of NTDs. The PCP pathway is also reported to be involved in secondary neurulation at the sacral level.
Genes related to caudal development: the T (BRACHYURY) transcription factor is essential for notochord and mesenchymal development, and notochord and caudal defects occur in mice with T gene variants. The FOXC2 gene is associated with lymphedema-distichiasis syndrome, but associations with some lumbosacral defects have also been reported. In caudal regression syndrome associated with maternal diabetes, disruption of the WNT and BMP signaling pathways is known to be involved.
Genetic counseling: for parents who have had a previous affected child, the recurrence risk is about 3–5%, and the risk for siblings is about 3–5%. When MTHFR TT homozygosity is confirmed, high-dose folic acid supplementation is recommended. Genome-wide association studies (GWAS) have reported multiple susceptibility loci associated with spina bifida, but gene panels for clinical use have not yet been standardized.
Sacral spina bifida (Q05.8) is the most common location of all spina bifida after the lumbar level (Q05.1–Q05.3, Q05.7). The reported distribution of lesions in spina bifida worldwide is, in order, lumbar (40–50%), sacral (20–25%), lumbosacral junction (15–20%), thoracic (5–10%), and cervical (5%). The overall incidence of spina bifida is about 0.3–1.0 per 1,000 births, decreasing to 0.2–0.5 per 1,000 births in countries implementing folic acid fortification policies.
Among sacral spina bifida, the subtype without hydrocephalus (Q05.8) has mild or absent Chiari II malformation and therefore tends to have a better neurological prognosis than the subtype with hydrocephalus. The proportion without hydrocephalus among all spina bifida patients (Q05.7–Q05.9 combined) is reported at about 20–30%, and the sacral level accounts for a considerable proportion of these. Spina bifida occulta (Q76.0) is an extremely common spinal variant observed in about 5–10% of the general population; it is mostly asymptomatic and is often not included in the NTD category.
Epidemiology in Korea: according to data from the Health Insurance Review & Assessment Service (HIRA) and the congenital anomaly registry program, the annual birth incidence of spina bifida (all of Q05) is about 1.0–2.0 per 10,000 births. It has tended to decrease since folic acid supplementation campaigns, but domestic data separately tallying the sacral-level subtype are limited. In Korea, Q05.8 is eligible for rare disease Special Copayment Reduction V179, and copayment reduction benefits are provided upon registration. Incidence may be relatively higher in groups with low access to prenatal care due to socioeconomic factors.
Regarding the sex ratio, a slightly higher incidence in girls tends to be reported for spina bifida overall, but some countries and studies are inconsistent. The sex difference in sacral-level lesions, as at the lumbar level, is not large. In developed countries, with improved prenatal ultrasound screening, decisions to terminate pregnancy are sometimes made for fetuses with severe spina bifida, so birth prevalence may be counted lower than the actual incidence.
The pathophysiology of sacral spina bifida is understood as centered on defects in secondary neurulation. The spinal cord below the lumbar level is formed not by primary neurulation but by the cavitation process of the caudal cell mass. In this process, densely packed undifferentiated cells form spaces internally, creating a spinal cord structure continuous with the neural tube. When a defect occurs in this complex remodeling process, spinal cord and vertebral defects at the sacral·coccygeal levels occur.
The sacral-level spinal cord contains the sacral (S2-S4) parasympathetic centers that control urination, defecation, and sexual function, as well as the motor and sensory fibers of the pudendal nerve. Damage at this level selectively impairs the neural control of the bladder, rectum, and sexual organs, with a pattern of relatively preserved lower limb strength. The absence of hydrocephalus means that Chiari II malformation is mild or absent and cerebrospinal fluid circulation is maintained, which indicates that upper nervous system (cerebral, cerebellar) function is not impaired.
Mechanism of tethered cord: when the spinal cord is tethered by scar tissue after surgery for sacral spina bifida, a lipoma, or a thickened filum terminale, it cannot ascend during growth and is subjected to continuous tension. This tension compresses microvessels within the spinal cord, causing reduced blood flow and metabolic impairment, and leads to tethered cord syndrome, in which lower limb strength, sensation, and bladder function progressively deteriorate. It worsens particularly during growth, and some recovery of function is possible after surgical untethering.
Mechanism of the absence of hydrocephalus: in typical myelomeningocele, Chiari II malformation causes hydrocephalus when reduced posterior fossa volume and spinal cord traction cause the cerebellar tonsils and brainstem to descend and block the outlets of the fourth ventricle. In sacral-level lesions, the spinal cord traction force is concentrated more caudally, so cerebellar descent is mild or does not occur, and cerebrospinal fluid circulation is therefore maintained. This is why sacral spina bifida is classified as the subtype without hydrocephalus (Q05.8).
The clinical symptoms of sacral spina bifida without hydrocephalus vary with the lesion level, extent, and degree of neurological damage. Lesions at the sacral level (S1–S5) mainly affect the function of the perineum, bladder, rectum, sexual organs, and distal lower limbs, while upper limb function and cognitive function are normal. Because there is no hydrocephalus, there are no symptoms related to increased intracranial pressure.
Bladder dysfunction: the sacral cord (S2-S4) is the parasympathetic control center of the bladder detrusor. Damage at this level causes neurogenic bladder, combining loss of detrusor contraction (acontractile bladder) and dysfunction of the internal and external urethral sphincters. Continuous dribbling of urine, increased residual urine, bladder overdistension, and recurrent urinary tract infections are the main symptoms. Conversely, detrusor overactivity may occur in some, so urodynamic studies are needed to differentiate the type.
Rectal·anal dysfunction: damage to the pudendal nerve (S2-S4) and pelvic splanchnic nerves causes reduced anal sphincter function, loss of rectal sensation, fecal incontinence, or chronic constipation. Patients cannot feel the urge to defecate, so fecal incontinence occurs repeatedly, which greatly interferes with social life and school adjustment.
Lower limb function: with S1-S2-level damage, weakness of ankle plantarflexion (calf muscles), weakness of toe flexion, and reduced intrinsic foot muscle function appear. At S3 and below, lower limb strength is nearly normal. Foot deformities (clubfoot, equinus) can arise from muscle imbalance. Loss of plantar sensation can lead to recurrent pressure ulcers and foot injuries.
Sexual dysfunction: in adulthood, erectile dysfunction (men), reduced sexual sensation (women), and ejaculatory dysfunction may occur. These result from damage to the sacral-origin control of the pudendal nerve and have an important effect on quality of life. Appropriate sexual counseling and use of assistive devices help.
Skin and external abnormalities: external signs such as a dermal sinus, lipoma, hairy patch, hemangioma, and skin pigmentation may be observed in the sacral region. These findings are important clinical clues suggesting the presence of an underlying spinal cord lesion (tethered cord, lipomyelomeningocele).
The physical signs of sacral spina bifida vary with the lesion type (open vs occult) and age. In newborns, a cystic lesion or skin abnormality in the sacral region is the main external sign, while in adults, bladder·rectal dysfunction and neurological findings are central.
External and skin signs: in open myelomeningocele, a cyst or exposed meninges on the dorsal sacrum are observed. In spina bifida occulta (forms with lipomyelomeningocele or dermal sinus), a sacral dimple (pathological significance if located above the anus, 2 cm or more in size, or with a base that cannot be seen), a midline dermal sinus, a fatty bulge, a nevus, or a hemangioma appear as external signs. When such findings are found, immediate spinal MRI evaluation is recommended.
Neurological signs: with S1-S2-level damage, loss of the ankle deep tendon reflex (Achilles tendon reflex), loss of the plantar reflex, and atrophy of the intrinsic foot muscles are observed. At the S2-S4 level, loss of the anal reflex (anal wink reflex), loss of perineal sensation, and loss of the bulbocavernosus reflex are confirmed. Distal lower limb strength shows a mild to moderate decrease depending on the lesion level.
Urologic signs: palpable bladder distension, continuous dribbling of urine, and on urodynamic studies findings of a low-pressure·overdistended bladder (flaccid bladder) or a high-pressure·overactive bladder (overactive bladder). On renal ultrasound, hydronephrosis and ureteral dilation are observed as long-term complications.
Anorectal signs: decreased anal sphincter tone, loss of the ability to sense stool in the rectum, and decreased sphincter squeeze pressure on anorectal manometry. An elevated sensory threshold to rectal distension appears.
Imaging findings: spinal X-ray confirms a posterior sacral vertebral arch defect. Spinal MRI assesses tethered cord, lipomyelomeningocele, connection of a dermal sinus with the spinal canal, and the presence of syringomyelia (syrinx). The feature of no hydrocephalus (normal-sized ventricles) or only a mild Chiari II malformation on head MRI is consistent with a diagnosis of Q05.8.
Prenatal screening for sacral spina bifida is carried out within the standard prenatal screening system applied to neural tube defects in general. Because ultrasound findings of sacral-level lesions may be less conspicuous than those at the lumbar level, the detection rate may be somewhat lower, so attention by the examiner is needed.
Maternal serum AFP (MSAFP): measured at 15–20 weeks of gestation; in open sacral myelomeningocele, AFP leaks out and is elevated. However, in skin-covered spina bifida occulta (lipomyelomeningocele, skin-covered myelomeningocele), AFP is normal, so screening with this test is not possible. Even with open sacral lesions, if the lesion is small, AFP elevation is mild and false negatives may occur.
Detailed fetal ultrasound: in the detailed structural ultrasound at 18–22 weeks of gestation, transverse scanning of the sacral vertebral arches is key. In a normal sacral transverse section, a complete arch shape enclosing the spinal canal should be observed, and a defect or splaying of the posterior arch is a pathological finding. Skin defects, cysts, and lipomas at the sacral level are also checked. If intracranial findings (ventricular size, cerebellar shape, lemon sign) are absent or mild, Q05.8 is suggested.
Fetal MRI: performed as a supplementary test when abnormal findings are suspected on ultrasound, it more accurately assesses the level and extent of the spinal cord lesion, the degree of Chiari malformation, and ventricular size. Skin-covered lesions (lipomyelomeningocele) are better assessed on MRI than on ultrasound.
Intensified follow-up of high-risk groups: in those with a history of a previous affected child, a family history of spina bifida, valproic acid use, or maternal diabetes, high-dose folic acid (5 mg/day) supplementation is given along with intensified prenatal ultrasound and, if needed, fetal MRI·amniotic fluid testing.
Screening for skin signs in newborns and children: in the neonatal examination after birth, skin abnormalities in the lumbosacral region (dimples, dermal sinus, lipoma, hemangioma) are carefully checked. In particular, for dimples located 2 cm or more above the anus or whose base cannot be seen, spinal ultrasound or MRI is performed immediately. In newborns, spinal ultrasound is a useful first-line imaging test without radiation exposure.
The diagnosis of sacral spina bifida is divided into two stages, prenatal and postnatal. Prenatal diagnosis is made by ultrasound and MRI, and postnatal diagnosis by integrating physical examination, neuroimaging, urodynamics, and neurophysiological testing.
Prenatal diagnosis: Q05.8 is considered when detailed structural ultrasound confirms a sacral vertebral arch defect, skin defect, or cyst and intracranial findings are absent or mild. The diagnosis is confirmed when fetal MRI confirms the extent of the spinal cord lesion, mild or absent Chiari II, and normal ventricular size. Open lesions are confirmed by amniotic fluid AFP and AChE testing, and accompanying chromosomal abnormalities are excluded by fetal karyotyping.
Postnatal physical examination: skin abnormalities in the sacral region (cyst, dermal sinus, lipoma, dimple) are checked, and lower limb strength, foot deformities, anal sphincter tone, and perineal sensation are assessed. The anal reflex (anal contraction on stimulation of the perianal skin) and the bulbocavernosus reflex are checked.
Spinal MRI: assesses sacral vertebral arch defects, tethered cord, lipomyelomeningocele, dermal sinus-spinal canal connection, and the presence of syringomyelia. Whole-spine MRI is performed to confirm the upper level of the lesion and the extent of syringomyelia. It is essential for surveillance of re-tethering during postoperative follow-up.
Head MRI/ultrasound: performed to check for hydrocephalus. Q05.8 is characterized by normal or mildly enlarged ventricles and no or mild Chiari II malformation. Because hydrocephalus can progress during growth, regular head imaging follow-up is needed.
Urodynamic studies: performed from the neonatal period to classify the type of bladder function. Bladder volume, detrusor pressure during filling, sphincter activity, and bladder compliance are measured. When a high-pressure bladder is confirmed, CIC and anticholinergics are started immediately to prevent upper urinary tract damage. Vesicoureteral reflux is assessed by renal ultrasound and voiding cystourethrography (VCUG).
Anorectal manometry: measures internal and external anal sphincter pressures, the rectoanal inhibitory reflex (RAIR), and the anal sensory threshold, and is used to classify the type of neurogenic bowel and establish a bowel management strategy.
Treatment of sacral spina bifida is carried out continuously from the neonatal period to adulthood with multidisciplinary collaboration among neurosurgery, urology, gastrointestinal surgery, orthopedics, and rehabilitation medicine.
Neonatal surgical treatment: in open sacral myelomeningocele, surgical closure is performed within 24–72 hours after birth. The cyst and meninges are dissected and closed with layered sutures. If the skin defect is large, skin plastic surgery is needed. Early closure prevents meningitis and secondary neurological damage.
Untethering of the tethered cord: in spina bifida occulta, untethering is performed when tethering of the spinal cord by a lipomyelomeningocele, thickened filum terminale, or dermal sinus is confirmed and there is neurological progression. Intraoperative neuromonitoring (IONM) minimizes neurological injury, and early intervention favors functional recovery.
Urologic management: the core of neurogenic bladder management is CIC. Anticholinergics (oxybutynin, tolterodine, solifenacin) are used for detrusor overactivity. Intravesical botulinum toxin injection is considered when the response to anticholinergics is insufficient. Augmentation cystoplasty is performed when a high-pressure bladder cannot be controlled with medication. Regular urodynamic studies and monitoring of renal function are essential.
Bowel management: along with a high-fiber diet, regular meals, and sufficient fluid intake, bowel training at a fixed time every day is carried out. Glycerin suppositories, bisacodyl suppositories, and small-volume enemas are used at set times to establish bowel control. MACE (Malone antegrade continence enema) surgery greatly improves quality of life in refractory patients.
Orthopedic treatment: equinus·clubfoot are treated with the Ponseti method, cast correction, and Achilles tenotomy. Lower limb orthoses (AFO, SMO) support walking function. When spinal deformity (scoliosis, kyphosis) progresses, bracing or spinal fusion is considered. Progression of deformities is monitored with regular orthopedic follow-up.
Rehabilitation and psychosocial support: a comprehensive rehabilitation plan including physical therapy, occupational therapy, and speech therapy is established. Psychosocial support for school adjustment, social participation, and independent living skills training, and linkage to self-help groups are important. A transition plan to adulthood is established in advance during adolescence to facilitate a smooth transfer from pediatric-centered to adult-centered care.
The prognosis of sacral spina bifida without hydrocephalus is generally among the most favorable in the spina bifida spectrum. Upper limb function, cognitive function, and proximal lower limb strength are preserved, so independent ambulation is possible in most patients.
Walking ability: about 80–90% of patients with sacral-level lesions maintain independent ambulation into adulthood without orthoses or with minimal orthoses. Foot deformities, weight gain, and spinal cord re-tethering are the main risk factors for decline in walking.
Urologic prognosis: if CIC and drug treatment are started from the neonatal period, upper urinary tract damage can mostly be prevented, and near-normal renal function can be maintained into adulthood. However, if urinary tract management is neglected, it can progress to recurrent urinary tract infections, high bladder pressure, hydronephrosis, and renal failure, so lifelong ongoing management is essential.
Rectal·bowel prognosis: fecal continence can largely be achieved with an ongoing bowel management program. Because it directly affects social participation and quality of life, an individualized bowel management plan is important.
Cognition and academics: because there is no hydrocephalus, cognitive function and academic ability are in the normal range in most cases. The risk of learning disabilities is markedly lower than in the subtype with hydrocephalus. Attention problems are reported in some, but the effect on overall cognitive level is minimal.
Life expectancy: the life expectancy of patients with sacral spina bifida receiving appropriate management is reported to be into the 60s–70s or beyond, and the main causes of death are renal failure (urologic complications), pressure ulcer infections, and cardiopulmonary complications. Long-term follow-up at a specialized spina bifida clinic is key to improving life expectancy.
Prevention of sacral spina bifida requires a systematic approach of primary (prevention of occurrence), secondary (early diagnosis), and tertiary (prevention of complications) prevention.
Primary prevention — folic acid supplementation: all women who may become pregnant are advised to take folic acid 400–800 μg/day from 1 month before pregnancy through the first 3 months of pregnancy. For high-risk groups (previous affected child, family history, valproic acid use, maternal diabetes), high-dose folic acid of 5 mg/day is prescribed. Introduction and expansion of folic acid food fortification policies are effective for population-level prevention.
Primary prevention — management of risk factors: preconception diabetes control (HbA1c <6.5%), management of obesity, review of alternative drugs to valproic acid, and prevention of high fever in early pregnancy are important. An antiepileptic drug management plan for pregnant women with epilepsy is established in collaboration between neurologists and obstetrician-gynecologists.
Secondary prevention — prenatal screening: MSAFP at 15–20 weeks of gestation and detailed structural ultrasound at 18–22 weeks of gestation are included in standard prenatal care. Careful ultrasound assessment of the sacral level is performed, and abnormal findings are confirmed with fetal MRI and amniotic fluid testing. High-risk groups receive intensified follow-up management.
Tertiary prevention — early registration for specialized care: immediately after birth, the patient is registered at a multidisciplinary spina bifida clinic, and urologic, bowel, neurological, and orthopedic management begins from the neonatal period. Early treatment of neurogenic bladder, regular urodynamic studies, and early detection of tethering signs and surgery are key to preventing complications. Skin protection education (prevention of pressure ulcers in areas with sensory loss), oral hygiene, completion of vaccinations, and regular checkups are included in long-term health management.